Innovating Works

IRCCS AOU BO

Desconocido
SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applica... SYNTHIA is an ambitious collaboration between public and private institutions to facilitate the responsible use of Synthetic Data (SD) in he...
2024-08-09 - 2029-08-31 | Financiado
BIOTOOL-CHF: BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart fai... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Heart failure (HF) is a chronic clinical condition involving up to 6.5 million people in Europe, the most frequent cause of hospitalization...
2023-10-01 - 2028-09-30 | Financiado
HORUS: Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 "Solid organ transplantation (SOT) is the treatment of choice for end-stage organ failure but the immunosuppressive drugs used to prevent gr...
2022-05-30 - 2027-10-31 | Financiado
ECLIPSE: ECL based Infectious Pathogen bio SEnsor "Infectious diseases are a threat to mankind since their appearance in human history. Despite the advances in science and technologies, such...
2022-03-22 - 2025-10-31 | Financiado
SPIOMET4HEALTH: PCOS IN ADOLESCENT GIRLS AND YOUNG WOMEN TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-BHC-2018-2020 Polycystic Ovary Syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affectin...
2021-02-01 - 2026-03-31 | Financiado
RETENTION: heaRt failurE paTient managEment and iNTerventIOns usiNg continuous patient monitoring outside hospi... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-BHC-2018-2020 Heart failure (HF) is a prominent chronic disease, despite efforts in improving its prevention, diagnosis and treatment, represents the lead...
2021-01-22 - 2025-04-30 | Financiado
GenoMed4ALL: Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-FA-DTS-2018-2020 GENOMED4ALL will support the pooling of genomic, clinical data and other -omics health data (data EHR, PET, MRI and CT , Next Generation Se...
2020-12-04 - 2024-12-31 | Financiado
ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS CoV 2 Pandemic ORCHES... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020-2 The ORCHESTRA project provides an innovative approach to learn from the SARS-CoV-2 health crisis and derive recommendations for increasing p...
2020-11-06 - 2024-11-30 | Financiado
DISCOvERIE: Development dIagnostic and prevention of gender related Somatic and mental COmorbitiEs in iRritable... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-BHC-2018-2020 Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable b...
2019-12-13 - 2024-12-31 | Financiado
DECISION: DECOMPENSATED CIRRHOSIS IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-BHC-2018-2020 In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. developm...
2019-12-05 - 2025-09-30 | Financiado
PAPA-ARTIS: Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with Minimally Invasive... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-SC1-2016-2017 Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue t...
2016-12-12 - 2024-09-30 | Financiado
TREGeneration: Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoieti... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un H2020: H2020-PHC-2014-2015 Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg...
2014-12-01 - 2021-12-31 | Financiado
GANNET53: A drug strategy targeting heat shock protein 90 to combat metastatic p53 mutant ovarian cancer. IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA participó en un FP7: Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of a...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.